Paul Tudor Jones Akero Therapeutics, Inc. Transaction History
Tudor Investment Corp Et Al
- $15.5 Billion
- Q1 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 36,195 shares of AKRO stock, worth $850,582. This represents 0.01% of its overall portfolio holdings.
Number of Shares
36,195Holding current value
$850,582% of portfolio
0.01%Shares
5 transactions
Others Institutions Holding AKRO
# of Institutions
193Shares Held
74.2MCall Options Held
429KPut Options Held
591K-
Janus Henderson Group PLC London, X06.12MShares$144 Million0.09% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$128 Million2.2% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$123 Million3.09% of portfolio
-
Wellington Management Group LLP Boston, MA5.21MShares$123 Million0.02% of portfolio
-
Black Rock Inc. New York, NY4.89MShares$115 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.09B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...